| abstract |
IT REFERS TO AN ORAL PHARMACEUTICAL COMPOSITION, INCLUDING: A) A COMPOUND OF 4-QUINAZOLINAMINES OF FORMULA (I) WHERE R1 IS Cl or Br; X IS CH, N or CF; Het IS THIAZOL, FURANE; N- {3-CHLORO-4 - [(3-FLUOROBENZYL) OXY] PHENYL} -6- [5 - ({[2- (METHANOSULFONYL) ETHYL] AMINO} METHYL) -2-FURYL] -4-QUINAZOLAMINE (GW572016) OR DENOMINATED LAPATINIB, IN A QUANTITY OF BETWEEN 5 TO 85% BY WEIGHT OF THE COMPOSITION; B) AT LEAST ONE LINK BASED ON GELATINE, POVIDONE, CELLULOSE, AMONG OTHERS; IN AN AMOUNT INCLUDED BETWEEN 2 TO 11% BY WEIGHT OF THE COMPOSITION AND C) AT LEAST ONE DISINTEGRANT BASED ON SODIUM STARCH GLUCOLATE, ETILCELLULOSE, BENTONITE, AMONG OTHERS; IN AN AMOUNT INCLUDED BETWEEN 1 TO 10% BY WEIGHT OF THE COMPOSITION. SAID COMPOUNDS ARE INHIBITORS OF EGFR PROTEIN TYROSINE KINASE AND / OR erbB2, SO THEY ARE USEFUL IN THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS BREAST, LUNG, GASTRIC CANCERS, AMONG OTHERS |